Physician profile
Ling Chen
NPI 1962903914
$906.70
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $203 · 2022: $194 · 2023: $411 · 2024: $98.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $509.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.12 | 2021-2024 | Jardiance |
| Novo Nordisk INC | $159.57 | 2022-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $114.34 | 2021-2023 | Mounjaro |
| Abbvie INC. | $110.79 | 2021-2022 | |
| Exact Sciences Corporation | $70.68 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $43.33 | 2022-2023 | Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $43.08 | 2021 | |
| Almatica Pharma LLC | $31.38 | 2023 | Loreev Xr, Gralise |
| Novartis Pharmaceuticals Corporation | $30.00 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $26.15 | 2021 | |
| Janssen Biotech, INC. | $25.00 | 2024 | Akeega, Erleada |
| Janssen Pharmaceuticals, INC | $17.25 | 2023 | Xarelto |
| Glaxosmithkline, LLC. | $15.90 | 2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $15.00 | 2021 | |
| Horizon Therapeutics Plc | $14.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ling Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.